Arkolith/Insider Trading/NAMS/Form 4

Davidson Michael H.

Chief Executive Officer, DirectorNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Feb 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$10.6M
Net Open-Market Flow
-$10.6M
Transactions
13
10 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 26, 2026Option exercise(M)183K——643K
Feb 26, 2026Sell(S)165K$33.63$5.6M478K
Feb 26, 2026Sell(S)18K$34.44$617K174K
Feb 25, 2026Option exercise(M)58K——518K
Feb 25, 2026Sell(S)47K$35.11$1.6M472K
Feb 25, 2026Sell(S)10K$35.96$375K461K
Feb 25, 2026Sell(S)1K$36.68$48K460K
Feb 24, 2026Option exercise(M)65K——525K
Feb 24, 2026Sell(S)62K$36.13$2.2M463K
Feb 24, 2026Sell(S)3K$36.46$115K460K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 26, 2026Option exercise(M)183K—$0683K
Feb 25, 2026Option exercise(M)58K—$0866K
Feb 24, 2026Option exercise(M)65K—$0925K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-078718) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML